1. Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme.
- Author
-
Li Z, Guo M, Gu M, Cai Z, Wu Q, Yu J, Tang M, He C, Wang Y, Sun P, You Q, and Wang L
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Structure-Activity Relationship, Mice, Nude, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating chemical synthesis, Antineoplastic Agents, Alkylating therapeutic use, Xenograft Model Antitumor Assays, Cell Proliferation drug effects, Enzyme Inhibitors pharmacology, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors chemistry, Enzyme Inhibitors therapeutic use, Temozolomide pharmacology, Temozolomide therapeutic use, Drug Design, Drug Resistance, Neoplasm drug effects, Glioblastoma drug therapy, Glioblastoma pathology
- Abstract
The serine/threonine phosphatase family is important in tumor progression and survival. Due to the high conserved catalytic domain, designing selective inhibitors is challenging. Herein, we obtained compound 28a with 38-fold enhanced PP5 selectivity (PP2A/5 IC
50 = 33.8/0.9 μM) and improved drug-like properties (favorable stability and safety, F = 82.0%) by rational drug design based on a phase II PP2A/5 dual target inhibitor LB-100 . Importantly, we found the spatial conformational restriction of the 28a indole fragment was responsible for the selectivity of PP5. Thus, 28a activated p53 and downregulated cyclin D1 and MGMT, which showed potency in cell cycle arrest and reverse temozolomide (TMZ) resistance in the U87 MG cell line. Furthermore, oral administration of 28a and TMZ was well tolerated to effectively inhibit tumor growth (TGI = 87.7%) in the xenograft model. Collectively, these results implicate 28a could be a drug candidate by reversing TMZ resistance with a selective PP5 inhibition manner.- Published
- 2024
- Full Text
- View/download PDF